Recent Announcements
PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider
Veteran leaders join to accelerate commercialization and market access strategy as the company...
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Original Press Release Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200...
PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial
Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and...
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics, a pioneer in specialized phototherapy for neurodegenerative diseases, today...
Featured Article
Parkinson’s Treatment: Light Therapy and Beyond-Part 1
Innovations in Parkinson's Treatment: Exploring Light Therapy and Beyond Living with Parkinson's disease presents daily challenges, not just for those diagnosed but also for their families and caregivers. It's a journey that requires resilience, adaptation, and a...
Parkinson’s Treatment: Light Therapy and Beyond-Part 1
Innovations in Parkinson's Treatment: Exploring Light Therapy and Beyond Living with Parkinson's disease presents daily challenges, not just for those diagnosed but also for their families and caregivers. It's a journey that requires resilience, adaptation, and a...
Archived Content